Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026
Akamis Bio to Present Data from a Phase 1 Study of NG-348 in Patients with Advanced Epithelial Tumors at SITC 2026
Akamis Bio, a clinical-stage oncology company working to advance the standard of care in colorectal cancer, today announced an upcoming poster presentation of first-in-human clinical data from a Phase 1 study of NG-348 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2026, being held from November 4–8, in Phoenix, Arizona.
NG-348 is an intravenously delivered oncolytic immunotherapy designed to drive intratumoral expression of two membrane-bound proteins that provide key signals for T cell activation: anti-CD3 single-chain variable fragment (scFv) and CD80. Tumor-cell surface expression of these molecules triggers antigen independent T-cell activation within the tumor microenvironment (TME), enabling direct tumor cell killing. By combining direct T cell engagement with oncolysis, NG-348 stimulates a robust anti-tumor response locally within the TME while also offering the potential to overcome immunotherapy resistance. The Phase 1 study assessed the safety, tolerability and preliminary anti-tumor effects of NG-348 monotherapy in patients with metastatic or advanced epithelial tumors refractory to standard therapies.
Poster Presentation Details:
Title: Phase 1 first-in-human study of NG-348 – an oncolytic adenovirus expressing CD80 and anti-CD3 scFv in patients with advanced epithelial tumors
Abstract: #497
Date and Time: November 6, 2026, 10 a.m. – 2 p.m. and 5 p.m. – 7 p.m. MT
Location: Phoenix Convention Center, North Exhibition Halls 4–6
About Akamis Bio
Headquartered in Cambridge, Massachusetts, Akamis Bio is a clinical-stage oncology company developing systemically administered oncolytic immunotherapies to treat colorectal cancer, with an initial focus on locally advanced rectal cancer (LARC). Its proprietary Tumor-Specific Immuno-Gene (T-SIGn®) platform is designed to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, with its lead clinical-stage program, NG-350A, driving intratumoral expression of a CD40 agonist monoclonal antibody. To learn more, please visit www.akamisbio.com.
Media Contact:
Jason Glashow
Glashow Strategic Communications
Jason.Glashow@akamisbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103522854/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
This Once-Hot AI Stock Now Looks Deeply Undervalued
3 Stocks to Sell and 3 Stocks to Buy for November
The 10 Best Companies to Invest in Now
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
United States